Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?, 1st Edition

  • Published By:
  • ISBN-10: 1118511255
  • ISBN-13: 9781118511251
  • DDC: 338.4
  • Grade Level Range: College Freshman - College Senior
  • 136 Pages | eBook
  • Original Copyright 2013 | Published/Released May 2014
  • This publication's content originally published in print form: 2013

  • Price:  Sign in for price



This book offers a balanced view of the role of drug discovery in improving public health. The pharmaceutical industry frequently receives criticism for things like promoting unsafe drugs and relying on a broken and irreparable R & D pipeline. The author, former Pfizer president John LaMattina, tackles some of these issues. He addresses the progress that industry has made in improving its abilities to measure both risk and benefits of its new medicines, then tackles the issue of R&D productivity - the reasons for the drop-off and whether it is temporary or permanent. Next, he discusses where the industry should invest its R&D resources and, of the multitude of solutions being offered to fix R&D, which are of value and how a company should proceed in the difficult business climate that is now facing. Finally, he presents ideas for how the industry can rehabilitate its image.

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
1: The Four Secrets the Drug Companies Don't Want You to Know.
2: What Has Happened to R&D Productivity?.
3: Key Therapeutic Areas For Improving Health.
4: Improving R&D Output.
5: Restoring Pharma'S Image.
6: Final Thoughts.